Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease.
Cerebral inflammation as well as systemic immunological alterations has been reported in Alzheimer's disease (AD). We aimed to determine whether spontaneous and mitogen stimulated production of peripheral blood mononuclear cell (PBMC) cytokines, chemokines and chemokine receptors in clinically diagnosed patients with AD were unregulated. PBMC were purified from AD patients and from healthy controls. Supernatants were analyzed for cytokine levels by ELISA methods. mRNA expression was determined by RT-PCR. Expression of chemokine receptors CCR2 and CCR5 was determined by cytofluorimetric analysis. Both CCR5 and CCR2 expression were increased in AD patients respect to control subjects and the expression of CCR2 and CCR5 was more frequent on CD4+ and less frequent on CD8+ cells. Levels of Th1-type cytokine IFNgamma and chemokine RANTES were increased and levels of Th2-type cytokine IL-4 and chemokine MCP-1 were reduced in AD patients compared with those of control subjects. Acetylcholinesterase inhibitor pyridostigmine bromide (AChEI)-therapy reduced CCR2, CCR5, RANTES and IFNgamma expression and production in AD patients. CCR5, CCL5/RANTES, CCL2/MCP-1 and IFNgamma expression and production were increased in PBMC treated with amyloid-beta1-42. Addition of AChEI to PBMC suppresses CCL5/RANTES and IFNgamma. The observed patterns of cyto-chemokine involvement strengthen the questions regarding the inflammatory theory in AD, and raise a pathophysiologic role for selective alteration of cyto-chemokine network.
Department of Oncology and Neuroscience, University G. d'Annunzio, Chieti, Italy. mreale@unich.it
Marcella
M
Reale
Carla
C
Iarlori
Claudio
C
Feliciani
Domenico
D
Gambi
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000276:immunology*; D016229:Amyloid beta-Peptides / Q000097:blood; D001921:Brain / Q000276:immunology; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000097:blood; D018946:Chemokine CCL5 / Q000097:blood; D018925:Chemokines / Q000097:blood*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D008297:Male; D008609:Mental Status Schedule; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D010446:Peptide Fragments / Q000097:blood; D011729:Pyridostigmine Bromide / Q000494:pharmacology; D054390:Receptors, CCR2 / Q000097:blood; D019713:Receptors, CCR5 / Q000097:blood; D019707:Receptors, Chemokine / Q000097:blood*; D012016:Reference Values; D015854:Up-Regulation / Q000276:immunology
D016229:Amyloid beta-Peptides; C111835:CCL2 protein, human; C515334:CCR2 protein, human; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D018925:Chemokines; D002800:Cholinesterase Inhibitors; D016207:Cytokines; D010446:Peptide Fragments; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; C075222:amyloid beta-protein (1-42); D015847:Interleukin-4; D007371:Interferon-gamma; D011729:Pyridostigmine Bromide